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Abstract
While clozapine is the acknowledged superior pharmacotherapeutic for the treatment of
schizophrenia, the side effect profile, which includes potentially fatal complications, limits its
usefulness. Central administration of clozapine directly into the brain could circumvent many of the
side effect issues due to the dramatic reduction in dose and the limitation of the drug primarily to the
CNS. The present study demonstrates that clozapine can be formulated as a stable solution at
physiological pH, which does not have in vitro neurotoxic effects at concentrations which may be
effective at treating symptoms. Acute central administration improved auditory gating deficits in a
mouse model of schizophrenia-like deficits. Assessment of behavioral alterations in rats receiving
chronic central infusions of clozapine via osmotic minipump were performed with the open field and
elevated plus mazes. Neither paradigm revealed any detrimental effects of the infusion. While these
data represent only an initial investigation, they none-the-less suggest that central administration of
clozapine may be a viable alternate therapeutic approach for schizophrenia patients which may be
effective in symptom reduction without causing behavioral or neurotoxic effects.
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1. Introduction
A primary reason for the ineffective treatment of schizophrenia is the numerous drawbacks of
atypical antipsychotics, as currently used. Ineffective treatment is a consequence of medication
side effects, failure to achieve therapeutic dose, and problems with patient compliance.
Prospective studies, with up to 20 years of follow-up, have demonstrated that 50-70% of
schizophrenia patients have a persistent course of illness and only 20-30% of patients are able
to lead somewhat normal lives (Fleischhaker et al, 2005).
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Clozapine has long been known as a superior medication, as highlighted in the recently
published NIH-sponsored CATIE trial for the treatment of schizophrenia. This study
demonstrated that clozapine is superior to other atypical antipsychotics as well as the typical
antipsychotics (McEvoy et al, 2006). Older studies showed that clozapine is one of the most
effective oral atypical antipsychotics due to 1) superior improvement in positive and negative
symptoms, 2) efficacy in the treatment of refractory schizophrenia, and 3) reduction in patient
suicide risk (Reid et al, 1998, Volvavka et al, 2002, Azorin et al 2001, Buchanan et al, 1998).
Even when observational studies are considered, as opposed to clinical trials, clozapine has
been shown to have superior efficacy (Brambilla et al 2002) particularly with refractory
patients. However, clozapine has a 1% incidence rate of agranulocytosis and a 3% incidence
rate of neutropenia (Atkin et al, 1996, Alvir et al, 1993), potentially lethal systemic side effects
which limit its use. It has been reported that even among the patients who will consent to use
clozapine, 17% discontinue use due to systemic side effects (Iqbal et al, 2003). Design of a
less-toxic clozapine has been a pharmaceutical development goal for the last 25 years.
Central administration of clozapine directly into the ventricular space via a chronically
implanted catheter can potentially meet the criterion of reduced toxicity and, when combined
with implantation of a programmable pump system such as those currently used for intraspinal
drug delivery, has the potential to significantly benefit patient adherence. Ventricular
administration of opiates has been shown to have minimal and accepted complications in a
Cochrane review of 250 published cases of cancer related pain (Ballantyne et al, 2006).
Intramuscular (IM) formulations (e.g. rispiradone, olanzapine and haloperidol) do not
significantly avoid systemic exposure and are also limited by the inability to halt medication
absorption after injection. Transdermal atypical antipsychotics currently under development
may improve compliance, eliminate the pain of IM injections, and permit abrupt
discontinuation, but are still limited by constant dosing, and more importantly, unaltered
peripheral side effect profile. These side effects are the most profoundly limiting issue in
antipsychotic administration, reducing patient acceptance of the medication, potentially
resulting in patient illness (e.g., liver toxicity and cardiac conduction deficits) (Lublin et al
2005; Iqbal et al 2003; Miller 2000) and mortality (e.g., bone marrow failure).
The development of formulations for clozapine for central administration is relatively
unexplored. As noted in the Kapur study (Kapur et al 2003), it is difficult to attain the
concentrations required for central administration with drugs as insoluble as clozapine. The
present studies assessed formulation of clozapine using hydroxypropyl-β–cyclodextrin
(HPBCD), a compound with demonstrated acceptable toxicity when administered intrathecally
(Yaksh et al 1991, Jang et al, 1992). In vitro toxicology was performed to establish an indication
of the level of neurotoxicity of direct application of HPBCD alone and clozapine formulated
with HPBCD. Efficacy of centrally administered clozapine was assessed in the DBA/2 mouse
model of deficient auditory gating in schizophrenia (Stevens et al, 1996), an accepted and
widely used animal model for schizophrenia drug development (Stevens et al, 1998; Hashimoto
et al, 2005; Radek et al, 2006). Finally, behavioral tests (open field and elevated plus mazes)
were performed to determine if central administration of clozapine produced any overt
behavioral alterations.
2. Methods
2.1 Solubility of formulated clozapine
Clozapine is insoluble at neutral pH, requiring either organic solvents or a low pH in order to
be solubilized (Merck Index, 2004). Because it is desirable to formulate drugs at physiological
pH (∼7.4), and because degradation accelerates under acidic conditions (Hasan et al 2002,
Yaksh 1999), HPBCD was used to solubilize clozapine at pH 7.4. Clozapine (1 mg/ml) was
solubilized under acidic conditions (pH ∼2.0 with HCl), increasing mole ratios of HPBCD
Abrams et al. Page 2
Schizophr Res. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(0-4) added and the solutions titrated back toward neutral pH with NaOH. Since precipitation
causes clozapine to form insoluble particles, light scattering (absorbance at 500 nm in a Hitachi
UV/VIS spectrophotometer; model U-2001) can be used to monitor the loss of solubility as
the formulation is alkalinized. After each addition of NaOH, the pH was determined and the
solution was transferred to a quartz cuvette to quantify clozapine precipitation via light
scattering. All formulations used in subsequent experiments utilized a HBPCD:clozapine molar
ration of 4:1, and were filter sterilized (0.22 μm) prior to ICV administration
2.2 In vitro neurotoxicology
A preliminary assessment of the toxicity of HBPCD, with or without clozapine, in primary
mouse cortical neuron cultures was performed. Primary cortical cultures were obtained from
fetal (E15) C57BL/6J mice as previously published (Donohue et al 2006). After dissection,
and cellular dissociation, the cells were washed with Dulbecco's Modified Eagle's Medium
with 10% fetal bovine serum. Following centrifugation, the cells were resuspended in plating
medium, counted with trypan blue and plated at a constant density of 6.5 ×104 cells per well
in a 96-well pre-coated plate. The plating media was 2% B27, 0.5 mM L-glutamine and 25
mM glutamic acid in NEUROBASAL medium (Invitrogen, Carlsbad, CA). On the 4th day,
half the media was replaced with fresh media that did not contain glutamic acid. The cultures
were maintained at 37° C in a humidified atmosphere of 5% CO2. On the 7th day of culture
incubation, half the media (40 m1) was replaced with media containing various concentrations
of the clozapine-HPBCD formulation or HPBCD alone. The cultures were incubated and cell
toxicity assayed at 24, 48 and 72 hours. Viability was assessed by the MTT (3-(4,5
diethylthiazol-2-yl)-2,5) diphenyltetrazolium bromide) assay, CellTiter 96 Non-radioactive
cell Proliferation Assay (Promega, Madison, WI) and by visual examination.
2.3 Auditory gating in DBA/2 mice with central clozapine administration
In order to assess the ability of centrally administered clozapine to improve deficient auditory
gating, DBA/2 male mice (20-25 g, Harlan Sprague Dawley, San Diego, CA) were anesthetized
with chloral hydrate (400 mg/kg, ip) and pyrazole (400 mg/kg, ip) to inhibit metabolism of the
chloral hydrate. The mice were then placed in a mouse adapter for the stereotaxic instrument
and the scalp incised. A burr hole was opened over the dorsal hippocampus and another over
the contralateral anterior cortex. A stainless steel, teflon-coated recording electrode was
lowered to the CA3 region of the dorsal hippocampus; final placement was determined by the
presence of complex spike activity typical of hippocampal pyramidal neurons (Miller and
Freedman, 1995). An identical electrode was placed on dura over the anterior cortex to act as
a reference. A third burr hole was opened over the lateral anterior ventricle on one side and a
26 gauge needle connected to a Hamilton microliter syringe was lowered to the anterior-lateral
ventricular space. Miniature earphones attached to hollow ear bars, placed at the externalization
of the aural canal, delivered the auditory stimuli. EEG responses to paired click stimuli (3000
Hz, 10 msec, 70 dB SPL, presented 0.5 sec apart, with 9 sec between pairs) were amplified
1000 times with bandpass filtering at 1-500 Hz and led to a computer for storage and analysis.
Data were collected and analyzed using the SciWorks acquisition system (DataWave,
Berthoud, CO). The responses to 16 pairs of stimuli were collected and averaged at 5-minute
intervals. The maximum negativity between 20 and 60 msec after the stimulus was selected
and measured relative to the preceding positivity. This composite component has been shown
to be less variable than either component alone (Hashimoto et al 2005). Three parameters were
measured per record: conditioning amplitude—the magnitude of the response to the first
stimulus, test amplitude—the magnitude of the response to the second stimulus, and TC ratio
—the ratio of the test amplitude/conditioning amplitude. A TC ratio of 0.4 or less is evidence
of normal auditory sensory inhibition. Four or five baseline records were obtained per mouse
prior to intracerebroventricular (ICV) clozapine administration (0.1, 0.5 or 1 μg in 1 μl) and
records were obtained at 5 minute intervals for 90-95 minutes after administration.
Abrams et al. Page 3
Schizophr Res. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.4 In vivo behavioral toxicity studies in rats
Male Sprague Dawley rats (250-300 g, Harlan Sprague Dawley, San Diego, CA) were
implanted with Alzet osmotic minipumps connected to brain infusion cannula (Durect,
Cupertino, CA) aimed at the lateral anterior ventricle. The pumps delivered saline, 10 or 17
mg/ml clozapine formulated in HPBCD (HPBCD:clozapine molar ratio = 4) at a rate of 0.25
μl/hr for 28 days. The rats were permitted to recover for 7 days prior to behavioral testing. On
the 7th day, one half of the rats in each group were tested in the elevated plus maze, while the
other half were tested in the open field maze. One week later (day 14 after pump implantation)
the groups were reversed. The elevated plus maze has been described elsewhere (Overstreet
et al 2003). Briefly, the study consisted of placing the rat in the center region of a black Plexiglas
+ shaped platform with 13 cm wide arms. Two of the arms were enclosed by 32 cm high walls
while the remaining 2 arms were open. The maze was elevated 51 cm off the floor. The
movements of the rat were computer tracked for the 5 minutes of the paradigm and the percent
time spent in each type of arm and distance traveled in each arm (open, closed or in the center
square) computer analyzed (Limelight 2, Actimetrics, Wilmette, IL). The open field maze has
also been described elsewhere (Overstreet et al 2003). The open field consisted of a 104 × 104
cm square of black Plexiglas with 39 cm high walls. The rat was placed near one side wall of
the field and allowed to explore at will for 5 minutes during which its activity was computer
monitored (Limelight 2, Actimetrics, Wilmette, IL). The field was divided into 3 regions (3
concentric squares), the outer region (adjacent to the walls), a middle region and the center
square. The percent time and distance traveled in each region were analyzed.
2.5 Statistical analysis
The sensory gating data were analyzed by repeated measures multivariate analysis of variance.
The open field and elevated plus maze data were analyzed with analysis of variance (SPSS,
Inc, Chicago, IL). Where statistical significance was found, Fisher's LSD a posteriori analysis
was performed.
3. Results
3.1 Clozapine Solubility
Because clozapine is an organic compound that is “practically insoluble” in water, it was
necessary to use an excipient to improve the solubility at physiological pH. Preliminary studies
indicated that HPBCD could provide this improved solubility. Figure 1 shows the level of light
scattering for solutions of clozapine formulated at different HPBCD-to-clozapine molar ratios
over a pH range of 2 to 12. As the solutions were titrated from acidic conditions toward
physiological pH, the clozapine formulation lacking HPBCD exhibited a sharp increase in light
scattering between pH 6 and 7, indicative of precipitation (Figure 1). Formulation of clozapine
at increasing molar ratios of HPBCD maintained solubility at progressively higher pH, and
molar ratios ≥ 3 completely prevented precipitation even under very alkaline conditions (pH
∼ 12). Upon visual inspection, the solutions formulated with adequate levels of HPBCD
maintained a clear, yellow appearance indicating that the clozapine remained fully solubilized.
Mole ratios of HPBCD-to-clozapine that maintained solubility at pH ∼12 were capable of
maintaining clozapine solubility at physiological pH for two months at 37°C.
3.2 In vitro toxicology
Assessment of in vitro neuronal toxicity demonstrated that HPBCD, alone at percent
concentrations ranging from 0.002 to 0.1, there was no significant reduction in cell viability
(Figure 2A) consistent with previous studies (Yaksh et al. 1991, Jang et al., 1992). When
clozapine at various concentrations ranging from 0 to 150 μM was formulated with HPBCD,
cells remained viable up to a clozapine concentration of 10 μg/ml (Figure 2B); approximately
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100-fold higher than that required for efficacy in the mouse auditory gating paradigm (see
section 3.3).
3.3 Auditory gating in DBA/2 mice with central clozapine administration
ICV clozapine improved auditory gating in the DBA/2 mouse in a dose dependent manner.
The lowest dose (0.1 μg) failed to show any significant change in conditioning (F(21,147)
=1.28, p=0.196) or test amplitude (F(21,147)=0.50, p=0.968) or in TC ratio (F(21,147)=0.94,
p=0.541) (Figure 3). In contrast, both the 0.5 and 1.0 μg doses showed significant improvement
in TC ratio (F(23,184)=3.07, p<0.001; F(23,115)=3.08, p<0.001, respectively) (Figures 4 and
5). Fisher's LSD a posteriori analyses showed extended periods of decreased TC ratio for both
doses. When the conditioning and test amplitudes for the 0.5 μg dose were analyzed, the
conditioning amplitude was found not to change significantly (F(23,184)=1.48, p=0.083) while
significant decreases were observed in the test amplitude (F(23,184)=2.80, p<0.001) (Figure
4), though only two time points attained significance in a posteriori analyses. Analyses of the
amplitudes of the conditioning and test responses for the 1.0 μg revealed significant changes
for both responses (F(23,115)=2.50, p<0.001; F(23,115)=2.58, p=0.001, respectively). Fisher's
LSD found significant increases in conditioning amplitude for most of the 95 minutes of
recording post injection, while the test amplitude was significantly reduced from 5-35 minutes
post injection (Figure 5).
3.4 In vivo behavioral studies in rats
Rats with chronic ICV administration of clozapine (10 or 17 mg/ml) in HPBCD were tested
in both the open field and elevated plus mazes to determine if there were any behavioral
alterations produced by the intervention. The data were compared to data from rats which had
received only saline ICV administration. Analysis of variance for the open field study,
analyzing percent time spent in specific regions and total distance traveled, showed significant
differences only in the distance traveled in the outer square of the maze (Table 1). Fisher's LSD
showed that the distance for the 17 mg/ml dose was significantly increased over that for saline
(Figure 6A). When the data for the elevated plus maze were similarly analyzed, the percent
time spent in the open arms of the maze was significantly different (Table 1) and a
posteriori analyses again showed that the percent time for the 17 mg/ml dose was significantly
elevated compared to the saline injection (Figure 6B).
4. Discussion
The present studies demonstrate that clozapine can be formulated to be soluble in aqueous
solution at pH 7.4 and remain fully dissolved for at least 2 months. Previous studies in both
humans (Light et al 2000; Nagamoto et al 1996; 1999) and mice (Simosky et al 2003) have
demonstrated that systemic administration of clozapine improves auditory gating. The present
studies show that when administered directly into the ventricles of the brain, clozapine shows
the same efficacy. The improvement in auditory gating at the highest dose was produced by
both an increase in the conditioning amplitude and a decrease in the test amplitude. This dual
action was most likely the result of indirect release of acetylcholine in the hippocampus
(Shirazi-Southall et al 2002) possibly through blockade of 5HT-3 receptors (Adler et al 1998).
Previous studies have demonstrated that stimulation of α7 nicotinic receptors reduces the test
amplitude (Stevens et al 1997) and stimulation of α4β2 nicotinic receptors increases
conditioning amplitude (Radek et al 2006). The combination of these two actions results in a
significantly reduced TC ratio as observed in the present studies. The in vitro neurotoxicology
studies suggest that, at the doses needed for improvement in auditory gating, the clozapine/
HPBCD combination is not toxic to neurons. An ICV injection of 1 μg of a clozapine
preparation would be diluted in a ventricular CSF fluid compartment of about 0.1 ml in rats
and thus the total clozapine ventricular concentration is expected to be below the toxicity level
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determined in vitro. Moreover, the in vitro values are obtained by adding drug to a pure
preparation of cells in culture with no barriers to transport or distribution. Therefore we would
expect that the in vivo concentrations that could achieve similar toxicity would have to be
higher than what was used in vitro. The behavioral testing suggests that there may be minimal
negative behavioral consequences. In the present studies, the increased activity observed in the
open field maze suggests that central clozapine does not induce sedation and the increased
entry into the open arms of the elevated plus suggests that, rather than anxiogenic, central
clozapine may be somewhat anxiolytic.
The recently published Catie study (McEvoy et al 2006) supports previous studies (Brambilla
et al 2002; Breier et al 1994; Claghorn et al 1987; Essock et al 1995) confirming clozapine as
the most efficacious drug for the treatment of schizophrenia, especially refractory cases.
However, clozapine has numerous side effects which limit its usefulness. These include very
serious complications such as agranulocytosis, cardiovascular/respiratory arrest and seizures,
as well as sedation, tachycardia, hyper-and hypotension, weight gain, hepatic effects,
constipation and fever (Miller 2006). The majority of these are peripheral in nature and would
be reduced or eliminated if administration of clozapine could be confined to the central nervous
system. Though side effects such as seizure and sedation would not be expected to be
significantly altered by central administration since it is thought that these side effects are
centrally mediated and the concentration at the synapse should be similar, if efficacy has been
achieved, regardless of the route of administration.
The data presented here using a rodent model of deficient auditory gating, demonstrate the
feasibility of administering clozapine centrally to produce improvements in sensory processing
in schizophrenia patients. The severity of auditory gating deficits has been correlated to positive
(Croft et al 2001), negative (Erwin et al 1998) and cognitive (Cullum et al 1993) symptoms of
schizophrenia. Further, improvements in auditory gating in patients have been correlated with
improvements in symptomotology of schizophrenia (Nagamoto et al 1999).
While these studies are only preliminary, they suggest that centrally administered clozapine
could be effective in human patients. The DBA/2 mouse model has proven efficacy in
predicting human improvement in auditory gating (Stevens et al 1998; Olincy et al 2006) and
is currently being used by several pharmaceutical companies in the development of nicotinic
agonists for schizophrenia. Clozapine itself is known to be an effective medication (Brambilla
et al 2002; McEvoy et al 2006) and if equivalent central delivery in humans can be developed,
there is a high likelihood of effectiveness. In support of this theory, a recent study showed
effective treatment of epilepsy with central administration of valproic acid (Serralta et al.
2006). Rather than spinal administration, as is used in treatment for chronic pain and spacticity
(Dones 2007; Koulousakis et al 2007; Richard and Menei 2007) it proposed that clozapine be
administered directly into the anterior lateral ventricles via an indwelling catheter. The catheter
would be connected to a standard abdominally implanted, programmable, refillable pump
similar to those currently used for intrathecal drug delivery (Levy 1997). Delivery into the
ventricles places the drug in relative proximity to the brain regions thought to be associated
with the symptoms of schizophrenia.
Although the present data are encouraging, there are factors which suggest that these studies
may not be predictive of human efficacy. These include the relative limitation of the auditory
gating model for drug testing, the limitations of all animal models of schizophrenia including
differences in metabolic rates and the unknown distribution in the large size human brain
compared with the rodent brain studied in this manuscript. The auditory gating model focuses
specifically on the gating deficit in schizophrenia and is most predictive of this particular aspect
of schizophrenia; although a recent study revealed improvement in some cognitive features of
schizophrenia concomitant with improvements in auditory gating (Olincy et al 2006). All
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animal models of schizophrenia have inherent limitations compared with the disorder in
humans (Powell et al 2006). Brain size of rodents is so dramatically smaller than humans that
if diffusion is a key limiting factor, brain size may be a very important barrier to central
administration. An approach to assess this would be to determine relative receptor occupancy
rates (Tauscher et al 2004). None-the-less, the present studies suggest that central
administration of clozapine for certain schizophrenia patients may be a reasonable new
treatment option which bears further testing.
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Figure 1.
Clozapine (1 mg/ml) was solubilized under acidic conditions, and the solution pH was titrated
up toward physiological pH. In the absence of HPBCD, clozapine precipitation at
approximately pH 6.5 is indicated by a dramatic increase in light scattering. Formulation of
clozapine at increasing HPBCD-to-clozapine mole ratios maintains solubility at progressively
higher pH, and precipitation is completely eliminated at mole ratios of 3:1 and 4:1. The ability
of HPBCD to maintain clozapine solubility, even under highly alkaline conditions (pH ∼12),
is an indicator of how effectively the drug is solubilized under these conditions.
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Figure 2.
A. This graph shows the cell viability at 24 hours at dilutions of HPBCD in culture media from
0.002% to 0.1%. There was no significant reduction in neuronal viability with the HPBCD
solutions used to solubilize clozapine. B. When clozapine was formulated with HPBCD and
added to the cells, significant toxicity was observed at final clozapine concentrations of 10
μg/ml (30 μM) or higher. This toxicity is similar to that reported to occur to human neutrophils
and monocytes (Gardner et al. 1998).
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Figure 3.
The 0.1 μg clozapine in 1.0 μl injection of clozapine into the anterior lateral ventricle of male
DBA/2 mice did not significantly alter any of the auditory gating variables tested. Four baseline
records (b) were obtained prior to ICV administration of the clozapine (at the arrow) and records
were obtained at 5 minute intervals for 90 minutes after injection. Data are mean ± SEM, n=8.
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Figure 4.
The 0.5 μg clozapine in 1.0 μl injection of clozapine into the anterior lateral ventricle of male
DBA/2 mice caused a significant reduction in test amplitude which produced a significant
reduction in TC ratio. While in increase in conditioning amplitude can be seen in the graph, it
failed to attain significance. Five baseline records (b) were obtained prior to ICV injection of
clozapine (at the arrow) and records were taken at 5 minute intervals for 95 minutes after
injection. Data are mean ± SEM; n=8; * p <0.05, ** p <0.01, Fishers' LSD.
Abrams et al. Page 13
Schizophr Res. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
The 1.0 μg clozapine in 1.0 μl injection of clozapine into the anterior lateral ventricle of male
DBA/2 mice produced significance increases in conditioning amplitude and decreases in test
amplitude which combined to produce a sustained decrease in TC ratio. Five baseline records
(b) were obtained prior to ICV injection of clozapine (at the arrow) and records were taken at
5 minute intervals for 95 minutes after injection. Data are mean ± SEM; n=8; * p <0.05, ** p
<0.01, Fishers' LSD.
Abrams et al. Page 14
Schizophr Res. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Male Sprague-Dawley rats were implanted with an osmotic minipump delivering either 10 or
17 mg/ml clozapine (0.25 μl/hr) directly into one anterior lateral ventricle. A. In open field
testing, the only significant change observed was an increase in distance traveled over the 5
minutes of testing, in the outer region of the open field maze suggesting that the clozapine did
not produce any sedation in these animals. B. When tested in the elevated plus maze, the rats
only showed significant changes in the amount of time spent in the open arms of the maze,
suggesting some anxiolytic effects of the centrally administered clozapine. Together these data
demonstrate that chronic central administration of clozapine did not produce any detrimental
behavioral effects in these rats. Data are mean ± SEM; n=4 per group; * p<0.05, Fisher's LSD.
Abrams et al. Page 15
Schizophr Res. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Abrams et al. Page 16
Table 1
ANOVA Results for Behavioral Paradigms
Paradigm Variable Region F(2,15) p
Open Field Percent time in region Outer 0.441 0.653
Middle 0.489 0.624
Center 0.887 0.435
Distance traveled in region Outer 5.177 0.022
Middle 1.201 0.332
Center 0.891 0.434
Elevated Plus Percent time in arm Closed 1.770 0.209
Open 3.483 0.061
Center 0.058 0.943
Distance traveled in arm Closed 1.637 0.232
Open 1.749 0.212
Center 0.209 0.814
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